Search Results

PROSPECT Assesses Impact of Nonculprit Lesions

September 25, 2009—Gregg W. Stone, MD, presented results from the PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) study showing that culprit and nonculprit lesions contribute equally to the risk of 3-year adverse events in acute coronary syndrome (ACS) patients treated with stents and medical therapy. The data were presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2009 annual scientific symposium in San Francisco and reported in the conference's newspaper, TCT Daily. Abbott Vascular (Santa Clara, CA) sponsored the study.

One-Year SPIRIT IV Results Support Xience V and Promus DES

September 23, 2009—Abbott Vascular (Santa Clara, CA) announced that Gregg W. Stone, MD, presented 1-year results from the SPIRIT IV trial at the Transcatheter Cardiovascular Therapeutics (TCT) 2009 scientific symposium in San Francisco. The SPIRIT IV data show that the Xience V achieved superiority in the key safety and efficacy measures of target lesion failure (TLF) and target lesion revascularization (TLR) compared to the Taxus Express paclitaxel-eluting coronary stent system (Boston Scientific Corporation, Natick, MA) at 1 year. The SPIRIT IV trial is one of the largest randomized clinical trials between two drug-eluting stents, with 3,690 patients enrolled, including more than 1,000 patients with diabetes, the company stated.

One-Year SPIRIT IV Results Support Xience V and Promus DES

September 23, 2009—Abbott Vascular (Santa Clara, CA) announced that Gregg W. Stone, MD, presented 1-year results from the SPIRIT IV trial at the Transcatheter Cardiovascular Therapeutics (TCT) 2009 scientific symposium in San Francisco. The SPIRIT IV data show that the Xience V achieved superiority in the key safety and efficacy measures of target lesion failure (TLF) and target lesion revascularization (TLR) compared to the Taxus Express2 paclitaxel-eluting coronary stent system (Boston Scientific Corporation, Natick, MA) at 1 year. The SPIRIT IV trial is one of the largest randomized clinical trials between two drug-eluting stents, with 3,690 patients enrolled, including more than 1,000 patients with diabetes, the company stated.

PROSPECT Study of Coronary Atherosclerosis Published

January 20, 2011—In the New England Journal of Medicine, Gregg W. Stone, MD, et al have published findings from PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree), a prospective natural history study of coronary atherosclerosis (2011;364:226-235).

SPIRIT IV Results Published, Cost-Effectiveness Analysis Presented

May 5, 2010—Abbott Vascular (Santa Clara, CA) announced that Gregg W. Stone, MD, et al have published findings from the SPIRIT IV trial in the New England Journal of Medicine (2010;362:1663–1674). Abbott Vascular also announced that David Cohen, MD, presented findings from a retrospective cost-effectiveness analysis of SPIRIT IV data on March 13 at the Cardiovascular Research Foundation's Optimizing PCI Outcomes symposium in Atlanta.

Analysis Favors Bivalirudin in STEMI Patients Undergoing Primary PCI

January 6, 2015—In the Journal of the American College of Cardiology, Gregg W. Stone, MD, et al published findings from a study that sought to examine the outcomes of procedural anticoagulation with bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitor (GPI) for primary percutaneous coronary intervention (PCI), given the evolution in primary PCI (2015;65:27–38).

SPIRIT IV Safety and Efficacy Results Published and Cost-Effectiveness Analysis Presented

May 5, 2010—Abbott Vascular (Santa Clara, CA) announced that Gregg W. Stone, MD, et al have published findings from the SPIRIT IV trial in the New England Journal of Medicine (2010;362:1663–1674). Abbott Vascular also announced that David Cohen, MD, presented findings from a retrospective cost-effectiveness analysis of SPIRIT IV data on March 13 at the Cardiovascular Research Foundation's Optimizing PCI Outcomes symposium in Atlanta.

Five-Year Results Presented From EXCEL Study

September 28, 2019— The Cardiovascular Research Foundation (CRF) announced that 5-year results from the EXCEL study were presented by Gregg W. Stone, MD, at TCT 2019, the 31st annual Transcatheter Cardiovascular Therapeutics scientific symposium, which is sponsored by CRF and held September 25–29 in San Francisco, California. The study was published simultaneously by Dr. Stone et al online in The New England Journal of Medicine.

EXCEL Investigators Issue Detailed Response to BBC and EACTS Claims on Trial Conduct and Data Interpretation

December 12, 2019—Gregg W. Stone, MD, et al on behalf of the EXCEL leadership issued a response to the recent news reports and society statements questioning the conduct and data of the EXCEL trial.

InfraReDx Initiates CANARY Trial With LipiScan IVUS System

July 13, 2011—InfraReDx, Inc. (Burlington, MA) announced commencement of the CANARY (Coronary Assessment by Near-Infrared [NIR] of Atherosclerotic Rupture-Prone Yellow) clinical trial with the enrollment of the first patient.

COAPT Evaluates Abbott's MitraClip to Treat Secondary Mitral Valve Regurgitation in Heart Failure Patients

September 23, 2018—The Cardiovascular Research Foundation (CRF) announced that findings from the randomized COAPT trial were presented by Gregg W. Stone, MD, at TCT 2018, the 30th annual Transcatheter Cardiovascular Therapeutics scientific symposium, which is sponsored by CRF and held September 21–25 in San Diego, California. The findings were simultaneously published online by Dr. Stone et al in The New England Journal of Medicine.

Analysis of ABSORB Trials Evaluates Effect of Technique on Outcomes After BVS Implantation

December 11, 2017—An analysis of the effect of technique on outcomes after bioresorbable vascular scaffold (BVS) implantation in the ABSORB trials was published by Gregg W. Stone, MD, et al in Journal of the American College of Cardiology (JACC; 2017;70:2863–2874). The ABSORB trials assessed clinical outcomes after implantation of the Absorb everolimus-eluting poly-L-lactic acid–based BVS (Abbott Vascular).

Royal Philips Commences DEFINE GPS Study

June 22, 2021—Royal Philips announced the commencement of the DEFINE GPS study with the first patient enrolled by Allen Jeremias, MD, at St. Francis Hospital in Roslyn, New York.

Pooled Meta-Analysis of 1-Year Data From Four Absorb Bioresorbable Scaffold Trials Published

March 28, 2016—One-year outcomes from a meta-analysis of Abbott Vascular’s Absorb bioresorbable scaffold (BVS) in patients with coronary artery disease (CAD) were published by Gregg W. Stone, MD, et al in The Lancet (2016;387:1277–1289).

Three-year EXCEL Data Evaluate Abbott Vascular's EES in Left Main CAD

October 31, 2016—Three-year results from the EXCEL trial were presented at TCT 2016, the 28th annual Transcatheter Cardiovascular Therapeutics scientific symposium in Washington, DC, and simultaneously published online ahead of print by Gregg W. Stone, MD, et al in The New England Journal of Medicine.

Two-Year ADAPT-DES Analysis Supports Use of IVUS in Stent Placement

October 29, 2013—Volcano Corporation (San Diego, CA) announced 2-year outcomes from an analysis of use of intravascular ultrasound (IVUS) in the Cardiovascular Research Foundation (CRF)'s ADAPT-DES study, which is led by principal investigator Gregg W. Stone, MD, of the CRF. The analysis results were presented by study investigator Bernhard Witzenbichler, MD, at the CRF's TCT 2013: Transcatheter Cardiovascular Therapeutics conference in San Francisco, California.

HORIZONS-AMI Finds Bivalirudin Reduces Cardiac Mortality in STEMI Patients Undergoing Primary PCI

January 7, 2014—Data on the reduction in cardiac mortality with bivalirudin in patients with and without major bleeding from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) clinical trial were published by Gregg W. Stone, MD, et al in the Journal of the American College of Cardiology (2014:63:15–20).